NSE as a Predictor in Small Cell Lung Cancer
Author Information
Author(s): L.G.M. J0rgensen, K. 0sterlind, H.H. Hansen, E.H. Cooper
Primary Institution: Rigshospitalet, Hvidovre Hospital, Leeds University
Hypothesis
Can serum neuron specific enolase (NSE) predict response duration in small cell lung cancer (SCLC)?
Conclusion
NSE levels before therapy are significant predictors of response duration in SCLC patients.
Supporting Evidence
- NSE levels correlate with the extent of disease in SCLC patients.
- Patients with limited disease had better complete remission rates.
- NSE and type of response were significant predictors of response duration.
Takeaway
Doctors can use a blood test for NSE to help understand how long a patient with small cell lung cancer might respond to treatment.
Methodology
The study analyzed clinical and biochemical characteristics of SCLC patients undergoing chemotherapy, focusing on NSE levels and their correlation with treatment response.
Limitations
The study did not include patients with unevaluable disease lesions or those who died within the first four weeks of treatment.
Participant Demographics
Median age was 64 years, with a male to female ratio of about 2:1.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website